Use of dapagliflozin in patients with advanced diabetic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Sodium-glucose cotransporter-2 (SGLT2) inhibitors promote glucosuria, aiding overweight diabetic patients.
• These agents are generally contraindicated in advanced chronic kidney disease (CKD) due to potential renal function decline.
• Effective glucose management in diabetic CKD patients remains a clinical challenge.

Purpose of the Study:

• To investigate the safety and efficacy of SGLT2 inhibitors in patients with advanced CKD.
• To explore the role of adequate hydration in mitigating potential adverse effects of SGLT2 inhibitors in this population.
• To assess the impact of SGLT2 inhibitor therapy on glycemic control, weight, and renal function in advanced CKD.

Main Methods:

• Retrospective case review of five patients with advanced CKD treated with dapagliflozin.
• Monitoring of glycemic control (HbA1c, blood glucose levels).
• Assessment of renal function (e.g., eGFR, serum creatinine) and body weight.

Main Results:

• Patients experienced significant weight reduction.
• Marked improvement in glycemic control was observed.
• No aggravation of renal function was noted during the study period.
• Therapeutic benefits were achieved without compromising kidney health.

Conclusions:

• SGLT2 inhibitor therapy, specifically dapagliflozin, may be beneficial for diabetic patients with advanced CKD.
• Adequate hydration appears to be a crucial factor in preventing adverse renal events.
• This approach offers a potential strategy for managing diabetes in complex CKD cases.